BIOA

Bioage Labs

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/05/26

Business Summary

BioAge Labs is a clinical-stage biotechnology company focused on developing therapeutics targeting the biology of aging to treat metabolic and age-related diseases. The company generates cash through equity financing rather than operating income, funding research programs that aim to advance drug candidates into clinical trials. Its moat, if realized, comes from proprietary datasets linking aging biology to therapeutic targets and the intellectual property surrounding its drug candidates. However, until those candidates translate into approved products and commercial revenue, the moat remains scientific rather than economic.

VALUATION

P/E

-

Market Cap ($M USD)

$718

Forward P/E

-

PEG

-

PRICE TO SALES

64.5

PRICE TO BOOK

2.6

EV / EBITDA

-5.6

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$2.24

Next Year EPS Growth Estimate

-$2.78

Next Year Revenue Growth Estimate

-73.60%

Return on Equity (ROE)

-29.60%

Operating Margin

-1031.50%

Debt-to-Equity

0

Piotroski F-Score

4

Altman Z-Score

17.4

Return on Invested Capital (ROIC)

-30.50%%

Current Ratio

14.2

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is a highly speculative, balance-sheet-heavy biotech trading at a $718M market cap with no earnings, negative EPS of -5.6, and no Forward P/E, meaning there is zero valuation anchor tied to profitability. A Price/Sales ratio of 64.5 is extreme for a company with a -29.60% operating margin and -30.50% ROIC, signaling the market is pricing in distant optionality rather than tangible performance. The Altman Z-Score of 17.4 indicates virtually no near-term bankruptcy risk, reinforced by a 14.2 current ratio, but that strength is liquidity-based—not operational. This is not a mispriced compounder; it is a cash-rich clinical-stage bet with severe execution risk and no earnings visibility.

AI Exposure / Tech Reliance

As a Drug Manufacturers - Specialty & Generic company, BIOA operates in a sector increasingly shaped by AI-driven drug discovery and biomarker identification. Healthcare R&D platforms that integrate computational biology can compress timelines and reduce capital intensity, but none of that is visible in current financial metrics. With negative margins and no earnings base, technological leverage is still theoretical rather than reflected in operating performance.

The Bull Case

A speculative GARP investor could argue the 17.4 Altman Z-Score and 14.2 current ratio provide an unusually strong liquidity cushion for a company with deeply negative earnings, dramatically lowering insolvency risk despite -73.60% ROE. Institutional ownership at 53.33% suggests serious capital is already involved, potentially signaling informed conviction in pipeline value not captured in current revenue metrics. A Piotroski F-Score of 4 is not strong, but it is not catastrophic either—it implies operational stability rather than collapse. At 2.6x book value, the equity is not trading at an absurd multiple to its net assets, which could attract deep value biotech specialists betting on clinical inflection points.

The Bear Case

The bear case is overwhelming. A Price/Sales ratio of 64.5 combined with -29.60% operating margins and -30.50% ROIC means capital is being destroyed at scale. Debt/Equity of -1031.50% is a structural red flag, signaling a severely distorted capital structure likely driven by accumulated deficits, while EPS of -5.6 and expected EPS next year of -2.24 confirm there is no path to profitability in the near term. Sales Growth Next Year of -$2.78 suggests contraction rather than scaling, and the absence of P/E, PEG, dividend, or yield removes every traditional valuation backstop—this is a binary biotech wager, not an investment grounded in financial performance.

Market Sentiment & Smart Money

Short Interest %

3.50%

Analyst Consensus

1.88

Average Analyst Price Target

$53.33

Institutional Ownership %

61.30%

1-Year Beta

1.24

Insider Buying % (6 Mo)

2.40%%

Distance to 52-Week High

67.50%%

Distance to 52-Week Low

479.00%%